Cargando…

Clinical benefit of platinum doublet combination therapy in older adults with advanced non‐small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan

BACKGROUND: Previous trials suggest that older adults with non‐small cell lung cancer (NSCLC) derive benefit from platinum doublet combination therapy, but its superiority is controversial. Although geriatric assessment variables are used to assess the individual risk of severe toxicity and clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimokawa, Mototsugu, Kanazu, Masaki, Saito, Ryusei, Mori, Masahide, Tamura, Atsuhisa, Okano, Yoshio, Fujita, Yuka, Endo, Takeo, Motegi, Mitsuru, Takata, Shohei, Kita, Toshiyuki, Sukoh, Noriaki, Mizuki, Fumitaka, Takenoyama, Mitsuhiro, Atagi, Shinji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260489/ https://www.ncbi.nlm.nih.gov/pubmed/37073452 http://dx.doi.org/10.1111/1759-7714.14904

Ejemplares similares

The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab
por: Matsubara, Taichi, et al.
Publicado: (2020)

Platinum‐combination chemotherapy with or without immune‐checkpoint inhibitor in patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy: A multicenter retrospective study
por: Hisakane, Kakeru, et al.
Publicado: (2023)

Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study)
por: Takamori, Shinkichi, et al.
Publicado: (2021)

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet
por: Cottrill, Hope, et al.
Publicado: (2018)

A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non‐small cell lung cancer harboring EGFR mutations (JMTO LC12‐01)
por: Asami, Kazuhiro, et al.
Publicado: (2022)

On the $ doublet in $
por: Astner, G, et al.
Publicado: (1970)

Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis
por: Ohmoto, Akihiro, et al.
Publicado: (2022)

Protocol for Identification and Removal of Doublets with DoubletDecon
por: DePasquale, Erica A.K., et al.
Publicado: (2020)

A randomized phase III study of docetaxel alone versus docetaxel plus S‐1 in patients with previously treated non‐small cell lung cancer: JMTO LC09‐01
por: Atagi, Shinji, et al.
Publicado: (2023)

Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials
por: Takada, Kazuki, et al.
Publicado: (2022)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
por: Shimokawa, Mototsugu, et al.
Publicado: (2022)

New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy
por: Koo, Dong-Hoe, et al.
Publicado: (2021)

Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients
por: Haratake, Naoki, et al.
Publicado: (2019)

Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
por: Joung, Eun Kyo, et al.
Publicado: (2021)

Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer
por: Gu, Yangchun, et al.
Publicado: (2021)

Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk
por: Shimokawa, Mototsugu, et al.
Publicado: (2021)

Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial
por: Iihara, Hirotoshi, et al.
Publicado: (2019)

Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients
por: Umeda, Takuro, et al.
Publicado: (2017)

Calaxin stabilizes the docking of outer arm dyneins onto ciliary doublet microtubule in vertebrates
por: Yamaguchi, Hiroshi, et al.
Publicado: (2023)

doubletD: detecting doublets in single-cell DNA sequencing data
por: Weber, Leah L, et al.
Publicado: (2021)

Inner lumen proteins stabilize doublet microtubules in cilia and flagella
por: Owa, Mikito, et al.
Publicado: (2019)

Incidence of chemotherapy discontinuation and characteristics of elderly patients with non-small cell lung cancer treated with platinum-based doublets
por: Alexa, Teodora, et al.
Publicado: (2014)

A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients
por: Mo, Hongnan, et al.
Publicado: (2016)

Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
por: Paik, Seung Sook, et al.
Publicado: (2018)

Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report
por: Taniguchi, Hirokazu, et al.
Publicado: (2021)

Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy
por: Takahashi, Toshiaki, et al.
Publicado: (2021)

Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer
por: Rittberg, Rebekah, et al.
Publicado: (2022)

Treatment of Stage IV Non–Small Cell Lung Cancer with Pembrolizumab in Combination with Platinum-Based Doublet Chemotherapy in Vietnam
por: Nguyen, Khanh Toan, et al.
Publicado: (2023)

Advances in doublet mechanics
por: Ferrari, Mauro, et al.
Publicado: (1997)

Doublet final focus
por: Autin, Bruno
Publicado: (1996)

The inert doublet model
por: Arias, C, et al.
Publicado: (2010)

Doublet final focus
por: Autin, B
Publicado: (1996)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

DoubletDecon: Deconvoluting Doublets from Single-Cell RNA-Sequencing Data
por: DePasquale, Erica A.K., et al.
Publicado: (2019)

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
por: Greystoke, Alastair, et al.
Publicado: (2017)

Complete metabolic response of metastatic castration‐resistant neuroendocrine carcinoma of the prostate after treatment with RRx‐001 and reintroduced platinum doublets
por: Ojemuyiwa, Michelle, et al.
Publicado: (2018)

Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
por: Hu, Weiheng, et al.
Publicado: (2016)

Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis: A case report
por: Yamasaki, Masahiro, et al.
Publicado: (2019)

Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes
por: Wang, Jiun-Long, et al.
Publicado: (2021)

Assessing Recent Time-Dependent Double-Hybrid Density Functionals on Doublet–Doublet Excitations
por: Van Dijk, Joshua, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_smhm1endcvikke7tjq9plvuff0